EUCTR2014-004248-36-Outside-EU/EEA进行中（未招募）不适用
A phase 3, Observed-Blind, Randomized, Multi-center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico. - V70_50
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 282
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to participate in this study, all subjects must meet ALL of the inclusion criteria described.
- •1. Individuals of >6 months through <72 months of age on the day of informed consent.
- •2. Individuals whose parent(s)/legal guardian(s) have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.
- •3. Individuals who can comply with study procedures.
- •4. Willingness to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 282
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Each subject must not have:
- •1. Progressive, unstable or uncontrolled clinical conditions.
- •2. Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study.
- •3. History of progressive or severe neurologic disorder, seizure disorder or Guillian-Barré syndrome.
- •4. Surgery planned during the study period that in the Investigator’s opinion would interfere with the study visits schedule.
- •5. Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
- •6. Any fatal prognosis of an underlying medical condition (<12 month life expectancy).
- •7. Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
- •8. Abnormal function of the immune system resulting from:
- •a. Clinical conditions.
- •b. Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to informed consent.
- •c. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent.
- •9. Received immunoglobulins or any blood products within 180 days prior to informed consent.
- •10. Received an investigational or non-registered medicinal product within 30 days prior to informed consent.
- •11. Study personnel as an immediate family or household member.
- •12. Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.
- •13. Received any influenza vaccine (licensed or investigational) or with laboratory
- •confirmed influenza within 6 months prior enrollment.
- •14. Received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrolment in this study or who are planning to receive any vaccine within 28 days from the study vaccines.
研究者
相似试验
进行中（未招募）
不适用
To Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with One Dose of Licensed Meningococcal ACWY Conjugate administered to Healthy Children 2-10 Years of Age.Prophylaxis for Neisseria meningitidis serogroup A, C, W, and YEUCTR2014-005161-72-Outside-EU/EEAovartis Vaccines & Diagnostics2,820
进行中（未招募）
1 期
A Phase III Efficacy Study with QIVc in Pediatric SubjectsProphylaxis of influenza virus infectionMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001857-29-Outside-EU/EEASeqirus UK Limited
进行中（未招募）
1 期
A Phase III Efficacy Study with QIVc in Pediatric SubjectsProphylaxis of influenza virus infectionMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001857-29-PLSeqirus UK Limited6,227
进行中（未招募）
1 期
A Phase III Efficacy Study with QIVc in Pediatric SubjectsProphylaxis of influenza virus infectionMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001857-29-LVSeqirus UK Limited3,830
进行中（未招募）
1 期
A Phase III Efficacy Study with QIVc in Pediatric SubjectsProphylaxis of influenza virus infectionMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001857-29-CZSeqirus UK Limited3,830